Clinical Trial

Effects of E-care Protocol in Patients With Coronary Artery Bypass Graft

Study acronym: CABG
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 7, 2026 (before its estimated August 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
Coronary artery disease (CAD) is a heart disease caused by the buildup of plaque inside the coronary arteries that restricts blood flow to the heart which leads to heart attack. If it involve more than one artery it will be more critical so the preferred treatment will be coronary artery bypass graft. Respiratory failure after Coronary Artery Bypass Grafting (CABG) is a serious complication with multifactorial causes i.e. pneumonia and atelectasis in inpatients. Postoperative pulmonary complications will be diagnosed using the Melbourne Group Scale (MGS), applied daily from postoperative day 1 to day 7. A score of ≥4 positive criteria will be used to identify PPCs. The scale's criteria will include chest radiograph findings, oxygen saturation, sputum characteristics, inflammatory markers, and ventilation data, physician diagnosis of pneumonia, readmission to ICU for respiratory reasons, prolong ventilation\> 24 hours, unplanned use of non-invasive ventilation.
Trial Details
NCT Number NCT07574411
Lead Sponsor Riphah International University
Conditions CABG
Enrollment 42 participants
Start Date 2026-05-10
Primary Completion 2026-08-02 (estimated)
Study Completion 2026-08-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-07